Does Pfizer’s consumer healthcare announcement herald a trend towards slimmer, more focused business models? Pfizer’s announcement that it is exploring a sale or spin-off of its consumer healthcare business comes hard on the heels of a similar decision by the German company Merck. This runs against the trend of a few years ago when there was a scramble by Big Pharma to get into the consumer health/OTC medicines market in order to spread the business risk as Rx drugs came un